Mumbai-based, a multinational pharmaceutical company Cipla on Tuesday has partnered with diagnostics firm Genes2Me to launch the COVID-19 RT PCR testing kit in India. With the launch of the “RT-Direct multiplex COVID-19 RT PCR”, the firm aims to expand its diagnostic offering, it said in a regulatory filing.
The testing kit is validated by the Indian Council of Medical Research and is much more advanced as compared to other testing kits. It can deliver results in just 45 minutes as the RT-Direct test protocol does not require any RNA extraction process.
It further added that the company will be involved in distributing RT-Direct multiplex COVID-19 RT PCR kit across the country and has begun supply for the same.
